CDC25A and breast carcinoma: In summary, here we have shown that treatment with CPX induced the phosphorylation of Cdc25A, which promoted the protein degradation of Cdc25A in rhabdomyosarcoma (Rh30) and breast cancer (MDA-MB-231) cells.